<DOC>
	<DOC>NCT01179477</DOC>
	<brief_summary>The purpose of this multicenter post-approval study is to evaluate the acute and chronic performance of the QuickFlex® μ 1258T left ventricular lead.</brief_summary>
	<brief_title>QuickFlex Micro Left Ventricular Lead Post Approval Study</brief_title>
	<detailed_description>The endpoints of the study are: - Complication free survival rate at 5 years for complications related to the LV lead - Electrical performance (capture threshold) of St. Jude Medical's QuickFlex®µ 1258T LV Lead</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Menthol</mesh_term>
	<criteria>Have an approved indication per ACC/AHA/HRS guidelines for implantation of a CRTD system or participated in the QuickFlex® μ1258T IDE study Have the ability to provide informed consent for study participation and be willing and able to comply with the prescribed followup tests and schedule of evaluations Have a hypersensitivity to a single 1.0mg dose of dexamethasone sodium phosphate or short term contact with heparin Have a life expectancy of less than 5 years due to any condition Be less than 18 years of age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Left heart pacing lead</keyword>
	<keyword>Cardiac resynchronization therapy (CRT)</keyword>
	<keyword>Heart failure</keyword>
</DOC>